View in EDS

A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors.

Saved in:

Bibliographic Details
Title:	A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors.
Authors:	Koyama T; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Yonemori K; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Sato J; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Katsuya Y; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Okada M; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Yoshida T; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Okano F; Toray Industries, Inc., New Frontiers Research Laboratories and New Projects Development Division, Kamakura, Kanagawa, Japan., Yamamoto N; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan. nbryamam@ncc.go.jp.
Source:	Investigational new drugs [Invest New Drugs] 2026 Apr 14. Date of Electronic Publication: 2026 Apr 14.
Publication Type:	Journal Article
Journal Info:	Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1573-0646
DOI:	10.1007/s10637-026-01609-z